In the Claims:

Please cancel claims 37-46. Please amend claims 3-21, 23, 25-27 and 29-36 as follows.

1. (Original) A compound of formula (I):



I

wherein:

R^1 is alkyl;

w is 0 or 1;

R^{11} is H or C_{1-3}alkyl;

Ring A is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

Ring B is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

a, b, c, f, g, and h are the same or different and are each independently 0 or 1;

d and j are the same or different and are independently 1 or 2;

each R^2 is the same or different and is independently selected from the group consisting of alkylene, alkenylene and alkynylene;

Y^1 and Y^2 are the same or different and are each independently selected from the group consisting of -O-, $-S(O)_q-$ and $-N(R^5)-$;

q is 0, 1 or 2;

each R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, Het, $-COR^5$, $-CSR^5$, $-CO_2R^5$, -COPh, $-CO_2Ph$, -C(O)Het, $-C(O)NR^5R^6$, $-C(S)NR^5R^6$, $-C(=NR^5)R^6$, $-C(=NR^5)NR^5R^6$, $-CR^5=N-OR^6$, $-OR^5$, $-OCOR^5$, $-S(O)_pR^5$, $-S(O)_2OH$, $-S(O)_pNR^5R^6$, $-NR^5R^6$, $-NR^5COR^6$, $-NR^5CO_2R^6$, $-NR^5SO_2R^6$, $-NO_2$, -CN, -SCN and $-N_3$;

each p is the same or different and is 0, 1 or 2;

m and n are the same or different and are each independently 0, 1, 2, 3, 4 or 5;

each R^5 and each R^6 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

Ph is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-CO_2R^5$, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$, $-R^2-(NR^5R^6)CO_2R^5$, Het, $-R^2$-Het, -CN and $-N_3$; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-CO_2R^5$, $-C(O)NR^5R^6$, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$, oxo, -CN and $-N_3$;

or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

2. (Original) The compound according to claim 1, wherein R^1 is methyl.

3. (Currently Amended) The compound according to claim 1 ~~any of claims 1-2~~, wherein Ring A is selected from the group consisting of aryl and 5-13 membered heteroaryl.

4. (Currently Amended) The compound according to claim 1 ~~any of claims 1-2~~, wherein Ring A is phenyl.

5. (Currently Amended) The compound according to claim 1 ~~any of claims 1-4~~, wherein Ring B is selected from the group consisting of phenyl, pyridine and pyrimidine.

6. (Currently Amended) The compound according to claim 1 ~~any of claims 1-4~~, wherein Ring B is phenyl.

7. (Currently Amended) The compound according to claim 1 ~~any of claims 1-6~~, wherein each R^2 is the same or different and is independently selected from the group consisting of alkylene and alkenylene.

8. (Currently Amended) The compound according to claim 1 ~~any of claims 1-7~~, wherein b is 0.

9. (Currently Amended) The compound according to claim 1 ~~any of claims 1-7~~, wherein b is 1 and Y^1 is selected from the group consisting of -O- and -N(R^5)-.

10. (Currently Amended) The compound according to claim 1 ~~any of claims 1-9~~, wherein g is 0.

11. (Currently Amended) The compound according to claim 1 ~~any of claims 1-9~~, wherein g is 1 and Y^2 is -O-.

12. (Currently Amended) The compound according to claim 1 ~~any of claims 1-11~~, wherein d is 1.

13. (Currently Amended) The compound according to claim 1 ~~any of claims 1-12~~, wherein j is 1.

14. (Currently Amended) The compound according to claim 1 ~~any of claims 1-13~~, wherein each R^3 is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, -COR^5, -CO_2R^5, -COPh, -$C(O)NR^5R^6$, -OR^5, -$S(O)_pR^5$, -$S(O)_pNR^5R^6$, -NR^5R^6, -NO_2, -CN and -N_3.

15. (Currently Amended) The compound according to claim 1 ~~any of claims 1-13~~, wherein d is 1 and R^3 is selected from the group consisting of H, halo, alkyl, Ph, -COR^5, -CO_2R^5, -COPh, -$C(O)NR^5R^6$, -OR^5, -NR^5R^6, -NO_2 and -CN.

Express Mail Label No.
EV 332065173 US

16. (Currently Amended) The compound according to claim 1 ~~any of claims 1-15~~, wherein each R^4 is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ph, Het, $-COR^5$, $-CO_2R^5$, $-C(O)NR^5R^6$, $-OR^5$, $-S(O)_pR^5$, $-S(O)_2OH$, $-S(O)_pNR^5R^6$, $-NR^5R^6$, $-NR^5COR^6$, $-NO_2$ and -CN.

17. (Currently Amended) The compound according to claim 1 ~~any of claims 1-15~~, wherein j is 1 and R^4 is selected from the group consisting of H, halo, alkyl, $-COR^5$, $-CO_2R^5$, $-C(O)NR^5R^6$, $-OR^5$, $-S(O)_pR^5$, $-S(O)_2OH$, $-S(O)_pNR^5R^6$ and $-NO_2$.

18. (Currently Amended) The compound according to claim 1 ~~any of claims 1-17~~, wherein m is 0, 1, 2 or 3.

19. (Currently Amended) The compound according to claim 1 ~~any of claims 1-18~~, wherein n is 1, 2, or 3.

20. (Currently Amended) The compound according to claim 1 ~~any of claims 1-19~~, wherein each R^5 and each R^6 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl and cycloalkyl.

21. (Currently Amended) The compound according to claim 1 ~~any of claims 1-19~~, wherein each R^5 and each R^6 are the same or different and are each independently selected from the group consisting of H and alkyl.

22. (Original) A compound selected from the group consisting of:

5-Methyl-7-phenyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(2-nitrophenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine;

7-(2-Bromophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(4-Fluorophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-[3-(trifluoromethyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

2,2-Dimethyl-*N*-(2-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)propanamide;

2,2,2-Trifluoro-*N*-(2-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)acetamide;

3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzonitrile;

7-(3-Bromophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromothien-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(5-Bromopyridin-3-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo-[5,1-*f*][1,2,4]triazin-2-amine;

Methyl 3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;

7-(5-Bromothien-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromophenyl)-*N*-(3-chloro-4-morpholin-4-ylphenyl)-5-methylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzamide;

(2*E*)-3-(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)prop-2-enamide;

5-Methyl-*N*-(4-nitrophenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-{3-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}ethanol;

4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]benzene-sulfonamide;

7-(2-Methoxyphenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenol;

2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl acetate;

5-Methyl-7-[4-(trifluoromethyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-Methyl-*N*-{4-[(5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}urea;

5-Methyl-7-phenyl-*N*-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)(phenyl)methanone;

7-(1,3-Benzodioxol-5-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo-[5,1-*f*][1,2,4]triazin-2-amine;

Methyl 4-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}benzoate;

5-Methyl-7-(3-phenoxyphenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Aminophenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(1*H*-Indol-2-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(5-nitro-1*H*-pyrrol-2-yl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1*H*-pyrrol-2-yl)-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1*H*-indol-3-yl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Furyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(1*H*-Indol-5-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

2-[(2-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)thio]benzonitrile;

5-Methyl-7-(2-{[3-(trifluoromethyl)phenyl]amino}phenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-quinolin-8-yl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;

N-Methyl-*N*-[4-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]urea;

N-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

2-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]ethanol;

4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzenesulfonamide;

N-[4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

N-[3-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]acetamide;

tert-Butyl 3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)benzylcarbamate;

4-({5-Methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenol;

5-Methyl-*N*-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(5-Fluoro-2-methoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-{2-[4-Methoxy-3-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)phenyl]ethyl}acetamide;

N-[5-(2-Aminoethyl)-2-methoxyphenyl]-5-methyl-7-[3-(trifluoromethyl)-phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(2,4-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(2,5-Dimethoxyphenyl)-5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

Ethyl 5-({5-methyl-7-[3-(trifluoromethyl)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-yl}amino)nicotinate;

2-{3-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}-ethanesulfonic acid;

5-Methyl-7-[3-(1*H*-pyrazol-4-ylethynyl)phenyl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

3'-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-3-carboxylic acid;

2-Amino-3-(3'-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo-[5,1-*f*][1,2,4]triazin-7-yl}-1,1'-biphenyl-4-yl)propanoic acid;

5-Methyl-7-[2'-(trifluoromethyl)-1,1'-biphenyl-3-yl]-*N*-(3,4,5-trimethoxyphenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

(2*Z*)-3-(3-{5-Methyl-2-[(3,4,5-trimethoxyphenyl)amino]imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)-3-phenylprop-2-enamide;

7-(3-{[5-(Ethylsulfonyl)-2-methoxyphenyl]amino}phenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(3-{[4-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl]amino}phenyl)-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-{[4-(1*H*-imidazol-1-yl)phenyl]amino}phenyl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-{3-[(3-Chloro-4-morpholin-4-ylphenyl)amino]phenyl}-5-methyl-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N,*N*-Dimethyl-1-{3-[(3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino] imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)amino]phenyl}-methanesulfonamide;

5-Methyl-7-[3-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}-amino)phenyl]-*N*-(3,4,5-trimethoxyphenyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-Cyclopropyl-3-[(3-{5-methyl-2-[(3,4,5-trimethoxyphenyl)amino] imidazo[5,1-*f*][1,2,4]triazin-7-yl}phenyl)amino]benzenesulfonamide;

7-(5-Bromo-2-thienyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Bromo-2-thienyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(tetrahydro-2H-pyran-4-yl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-[2-(methyloxy)phenyl]-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-[3-(methyloxy)phenyl]-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(2-Chlorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1H-indol-3-yl)-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(1-phenylethyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-(1-methyl-1H-indol-2-yl)-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(3-thienyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(3-Furanyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo-[5,1-*f*][1,2,4]triazin-2-amine;

7-(2-Furanyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo-[5,1-*f*][1,2,4]triazin-2-amine;

7-(4-Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(2-thienyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-Cyclopropyl-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-Cyclohexyl-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(2-FluorophenylFluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-N,7-bis[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-(phenylmethyl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

Express Mail Label No.
EV 332065173 US

7-(3-Fluorophenyl)-5-methyl-*N*-[4-(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-Cyclohexyl-5-methyl-*N*-[3,4,5-tris(methyloxy)phenyl]imidazo[5,1-*f*][1,2,4]triazin-2-amine;

7-(Cyclohexylmethyl)-5-methyl-*N*-[4-(methyloxy)phenyl]-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-[3,4-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-[3,5-Bis(methyloxy)phenyl]-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-{4-[(5-Methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-yl)amino]phenyl}acetamide;

5-Methyl-*N*-[4-(methylthio)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(4-{[2-(Dimethylamino)ethyl]oxy}phenyl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-phenyl-*N*-(4-{[2-(1-piperidinyl)ethyl]-oxy}phenyl)-imidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(3-{[2-(Dimethylamino)ethyl]oxy}phenyl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

N-Cyclohexyl-5-methyl-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-7-phenyl-*N*-(tetrahydro-2H-pyran-4-yl)imidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-(3-{[2-(4-morpholinyl)ethyl]oxy}phenyl)-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[4-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*,7-diphenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

5-Methyl-*N*-[3-(methyloxy)phenyl]-7-phenylimidazo[5,1-*f*][1,2,4]triazin-2-amine;

and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.

23. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1 ~~any of claims 1-22~~.

24. (Original) The pharmaceutical composition according to claim 23 further comprising a pharmaceutically acceptable carrier, diluent or excipient.

25. (Currently Amended) The pharmaceutical composition according to claim 23 ~~any of claims 23-24~~ further comprising a chemotherapeutic agent.

26. (Currently Amended) A method for the treatment of a condition mediated by PLK in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1 ~~any of claims 1-22~~.

27. (Currently Amended) A method for the treatment of a neoplasm susceptible to PLK in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1 ~~any of claims 1-22~~.

28. (Original) The method according to claim 27, wherein said neoplasm is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, gastric carcinoma, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma.

29. (Currently Amended) A method for the treatment of a PLK-mediated condition characterized by inappropriate cellular proliferation in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1 ~~any of claims 1-22~~.

30. (Currently Amended) A method for inhibiting proliferation of a cell, said method comprising contacting the cell with an amount of a compound according to claim 1 ~~any of claims 1-22~~ sufficient to inhibit proliferation of the cell, wherein said compound inhibits PLK.

31. (Currently Amended) A method for inhibiting mitosis in a cell, said method comprising administering to the cell an amount of a compound according to claim 1 ~~any of claims 1-22~~ sufficient to inhibit mitosis in the cell, wherein said compound inhibits PLK.

32. (Currently Amended) A process for preparing a compound according to claim 1 ~~any of claims 1-22~~, said process comprising reacting a compound of formula (X):



X

with a cyclization reagent.

33. (Currently Amended) A process for preparing a compound according to claim 1 ~~any of claims 1-22~~, said process comprising reacting the compound of formula (XIII):



XIII

with a compound of formula (VI):



VI

34. (Currently Amended) A process for preparing a compound according to claim 1 ~~any of claims 1-22~~ wherein:

Ring A is selected from the group consisting of cycloalkyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl;

each R^2 is the same or different and is alkylene;

each R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, Ph, Het, $-OR^5$, $-S(O)_pR^5$, $-S(O)_2OH$, $-S(O)_pNR^5R^6$, $-NR^5R^6$ and $-NR^5SO_2R^6$;

each R^5 and each R^6 are the same or different and are each independently selected from the group consisting of H, alkyl and cycloalkyl;

Ph is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$, Het, and $-R^2$-Het; and

Het is a monocyclic 5-6 membered heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, $-OR^5$, $-SO_2R^5$, $-SO_2NR^5R^6$, $-NR^5R^6$ and oxo; and

said process comprising coupling a compound of formula (XVIII):



XVIII

with a compound of formula (XIX):



XIX

wherein X is Cl, Br, I or triflate.

35. (Currently Amended) The process according to claim 32 ~~any of claims 32-34~~, said process further comprising the step of converting a compound of formula (I) to a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

36. (Currently Amended) The process according to claim 32 ~~any of claims 32-35~~ further comprising the step of converting a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof to another compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

37-46. (Canceled)

Express Mail Label No.
EV 332065173 US